Ticlopidine

Back to search
Scientific Name: Ticlopidine
Brand Name: Not Available
Company Owner: Roche palo alto llc, Actavis elizabeth llc, Apotex inc, Caraco pharmaceutical laboratories ltd, Genpharm inc, Mylan pharmaceuticals inc, Sandoz inc, Teva pharmaceuticals usa inc, Watson laboratories inc
Mechanism Of Action The active metabolite of ticlopidine prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of ticlopidine.
Description of the Drug: Ticlopidine is a platelet aggregation inhibitor used in the prevention of conditions associated with thrombi, such as stroke and transient ischemic attacks (TIA) .
Protein Data Bank:
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB00208